A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.
Identifieur interne : 001E32 ( Ncbi/Merge ); précédent : 001E31; suivant : 001E33A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.
Auteurs : Xiaoxing Huang [République populaire de Chine] ; Bin Lu ; Wenbo Yu ; Qing Fang ; Li Liu ; Ke Zhuang ; Tingting Shen ; Haibo Wang ; Po Tian ; Linqi Zhang ; Zhiwei ChenSource :
- PloS one [ 1932-6203 ] ; 2009.
Descripteurs français
- KwdFr :
- MESH :
- génétique : Vaccins atténués, Virus de la vaccine.
- métabolisme : Virus du SRAS.
- Animaux, Anticorps antiviraux, Femelle, Génomique, Souris, Souris de lignée BALB C, Système immunitaire, Tests de neutralisation, Vaccin antivariolique, Vaccination, Vaccins, Vecteurs génétiques.
English descriptors
- KwdEn :
- MESH :
- chemical , chemistry : Antibodies, Viral, Smallpox Vaccine.
- chemical , genetics : Vaccines, Attenuated.
- genetics : Vaccinia virus.
- metabolism : SARS Virus.
- Animals, Female, Genetic Vectors, Genomics, Immune System, Mice, Mice, Inbred BALB C, Neutralization Tests, Vaccination, Vaccines.
Abstract
Mucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara (MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (S) of SARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels ( approximately 2-3-fold) of anti- SARS-CoV neutralizing antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently 20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of MVTT-S-induced Nab responses were substantially (approximately 10-fold) higher than that induced via the intramuscular route in the same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination.
DOI: 10.1371/journal.pone.0004180
PubMed: 19159014
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001976
- to stream PubMed, to step Curation: 001976
- to stream PubMed, to step Checkpoint: 001954
Links to Exploration step
pubmed:19159014Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.</title><author><name sortKey="Huang, Xiaoxing" sort="Huang, Xiaoxing" uniqKey="Huang X" first="Xiaoxing" last="Huang">Xiaoxing Huang</name><affiliation wicri:level="4"><nlm:affiliation>Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei</wicri:regionArea><orgName type="university">Université de Wuhan</orgName><placeName><settlement type="city">Wuhan</settlement><region type="province">Hubei</region></placeName></affiliation></author><author><name sortKey="Lu, Bin" sort="Lu, Bin" uniqKey="Lu B" first="Bin" last="Lu">Bin Lu</name></author><author><name sortKey="Yu, Wenbo" sort="Yu, Wenbo" uniqKey="Yu W" first="Wenbo" last="Yu">Wenbo Yu</name></author><author><name sortKey="Fang, Qing" sort="Fang, Qing" uniqKey="Fang Q" first="Qing" last="Fang">Qing Fang</name></author><author><name sortKey="Liu, Li" sort="Liu, Li" uniqKey="Liu L" first="Li" last="Liu">Li Liu</name></author><author><name sortKey="Zhuang, Ke" sort="Zhuang, Ke" uniqKey="Zhuang K" first="Ke" last="Zhuang">Ke Zhuang</name></author><author><name sortKey="Shen, Tingting" sort="Shen, Tingting" uniqKey="Shen T" first="Tingting" last="Shen">Tingting Shen</name></author><author><name sortKey="Wang, Haibo" sort="Wang, Haibo" uniqKey="Wang H" first="Haibo" last="Wang">Haibo Wang</name></author><author><name sortKey="Tian, Po" sort="Tian, Po" uniqKey="Tian P" first="Po" last="Tian">Po Tian</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19159014</idno><idno type="pmid">19159014</idno><idno type="doi">10.1371/journal.pone.0004180</idno><idno type="wicri:Area/PubMed/Corpus">001976</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001976</idno><idno type="wicri:Area/PubMed/Curation">001976</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001976</idno><idno type="wicri:Area/PubMed/Checkpoint">001954</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001954</idno><idno type="wicri:Area/Ncbi/Merge">001E32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.</title><author><name sortKey="Huang, Xiaoxing" sort="Huang, Xiaoxing" uniqKey="Huang X" first="Xiaoxing" last="Huang">Xiaoxing Huang</name><affiliation wicri:level="4"><nlm:affiliation>Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, People's Republic of China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei</wicri:regionArea><orgName type="university">Université de Wuhan</orgName><placeName><settlement type="city">Wuhan</settlement><region type="province">Hubei</region></placeName></affiliation></author><author><name sortKey="Lu, Bin" sort="Lu, Bin" uniqKey="Lu B" first="Bin" last="Lu">Bin Lu</name></author><author><name sortKey="Yu, Wenbo" sort="Yu, Wenbo" uniqKey="Yu W" first="Wenbo" last="Yu">Wenbo Yu</name></author><author><name sortKey="Fang, Qing" sort="Fang, Qing" uniqKey="Fang Q" first="Qing" last="Fang">Qing Fang</name></author><author><name sortKey="Liu, Li" sort="Liu, Li" uniqKey="Liu L" first="Li" last="Liu">Li Liu</name></author><author><name sortKey="Zhuang, Ke" sort="Zhuang, Ke" uniqKey="Zhuang K" first="Ke" last="Zhuang">Ke Zhuang</name></author><author><name sortKey="Shen, Tingting" sort="Shen, Tingting" uniqKey="Shen T" first="Tingting" last="Shen">Tingting Shen</name></author><author><name sortKey="Wang, Haibo" sort="Wang, Haibo" uniqKey="Wang H" first="Haibo" last="Wang">Haibo Wang</name></author><author><name sortKey="Tian, Po" sort="Tian, Po" uniqKey="Tian P" first="Po" last="Tian">Po Tian</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (chemistry)</term><term>Female</term><term>Genetic Vectors</term><term>Genomics</term><term>Immune System</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>SARS Virus (metabolism)</term><term>Smallpox Vaccine (chemistry)</term><term>Vaccination</term><term>Vaccines</term><term>Vaccines, Attenuated (genetics)</term><term>Vaccinia virus (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux ()</term><term>Femelle</term><term>Génomique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Système immunitaire</term><term>Tests de neutralisation</term><term>Vaccin antivariolique ()</term><term>Vaccination</term><term>Vaccins</term><term>Vaccins atténués (génétique)</term><term>Vecteurs génétiques</term><term>Virus de la vaccine (génétique)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Viral</term><term>Smallpox Vaccine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Vaccinia virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Vaccins atténués</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Genetic Vectors</term><term>Genomics</term><term>Immune System</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Vaccination</term><term>Vaccines</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux</term><term>Femelle</term><term>Génomique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Système immunitaire</term><term>Tests de neutralisation</term><term>Vaccin antivariolique</term><term>Vaccination</term><term>Vaccins</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara (MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (S) of SARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels ( approximately 2-3-fold) of anti- SARS-CoV neutralizing antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently 20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of MVTT-S-induced Nab responses were substantially (approximately 10-fold) higher than that induced via the intramuscular route in the same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19159014</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.</ArticleTitle><Pagination><MedlinePgn>e4180</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0004180</ELocationID><Abstract><AbstractText>Mucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara (MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (S) of SARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels ( approximately 2-3-fold) of anti- SARS-CoV neutralizing antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently 20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of MVTT-S-induced Nab responses were substantially (approximately 10-fold) higher than that induced via the intramuscular route in the same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiaoxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wenbo</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Li</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Ke</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Tingting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haibo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Po</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linqi</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012900">Smallpox Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012900" MajorTopicYN="N">Smallpox Vaccine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19159014</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0004180</ArticleId><ArticleId IdType="pmc">PMC2613559</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 1998 Oct;72(10):8264-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9733870</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2004 Jun;20(6):645-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15242542</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Biol Stand. 1995;84:159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7796949</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Nov 25;23(2):215-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15531040</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2001 Apr 6;292(5514):69-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11393868</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 May 22;25(21):4213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17434244</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Des. 2007;13(19):2015-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17627535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2003 Sep;41(9):4068-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12958227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Am. 1976 Oct;235(4):25-33</Citation><ArticleIdList><ArticleId IdType="pubmed">788150</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 1992;158:25-38</Citation><ArticleIdList><ArticleId IdType="pubmed">1582244</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 2007;51(2):125-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17900219</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 May 10;335(2):242-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15840523</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Oct;77(19):10684-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12970455</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2863-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17113200</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS Res Hum Retroviruses. 2004 Dec;20(12):1335-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15650426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18209682</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1991 Dec 19-26;354(6354):520-2</Citation><ArticleIdList><ArticleId IdType="pubmed">1758494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci China B. 1990 Feb;33(2):188-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2111142</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2007 Jan;88(Pt 1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17170430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation><ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 Nov;86(Pt 11):2925-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16227213</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1986 Apr 10-16;320(6062):537-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3008002</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechnology. 1992;24:495-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1422060</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Immunol. 2005 Mar 01;4(1):2</Citation><ArticleIdList><ArticleId IdType="pubmed">15740619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Aug;76(15):7713-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12097585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1992 Dec 15;52(24):6917-25</Citation><ArticleIdList><ArticleId IdType="pubmed">1458480</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2004 Jun 15;38(12):1749-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15227622</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Microbiol Biotechnol. 2007 Oct;76(5):1131-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17581748</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteomics. 2007 May;7(10):1678-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17443847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1985 Aug;66 ( Pt 8):1819-23</Citation><ArticleIdList><ArticleId IdType="pubmed">2991446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Dec 17;25(52):8874-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18061316</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2005 Sep 1;339(2):164-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15993917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jun 15;25(25):4818-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17499893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol Methods. 2007 Sep;144(1-2):17-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17459491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1987 Oct;68 ( Pt 10):2587-98</Citation><ArticleIdList><ArticleId IdType="pubmed">2822841</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1989 Dec;7(6):484-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2609722</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Sep;9(9):1131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12925846</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Mar 11;428(6979):182-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15014500</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Aug 29;347(9):689-90; author reply 689-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12200560</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Chin Acad Med Sci Peking Union Med Coll. 1989;4(4):215-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2631120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2007 Jan;88(Pt 1):61-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17170437</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2007 Jun 1;195(11):1598-606</Citation><ArticleIdList><ArticleId IdType="pubmed">17471429</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2004 Oct;8 Suppl 2:S15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15491871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Hubei</li></region><settlement><li>Wuhan</li></settlement><orgName><li>Université de Wuhan</li></orgName></list><tree><noCountry><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name><name sortKey="Fang, Qing" sort="Fang, Qing" uniqKey="Fang Q" first="Qing" last="Fang">Qing Fang</name><name sortKey="Liu, Li" sort="Liu, Li" uniqKey="Liu L" first="Li" last="Liu">Li Liu</name><name sortKey="Lu, Bin" sort="Lu, Bin" uniqKey="Lu B" first="Bin" last="Lu">Bin Lu</name><name sortKey="Shen, Tingting" sort="Shen, Tingting" uniqKey="Shen T" first="Tingting" last="Shen">Tingting Shen</name><name sortKey="Tian, Po" sort="Tian, Po" uniqKey="Tian P" first="Po" last="Tian">Po Tian</name><name sortKey="Wang, Haibo" sort="Wang, Haibo" uniqKey="Wang H" first="Haibo" last="Wang">Haibo Wang</name><name sortKey="Yu, Wenbo" sort="Yu, Wenbo" uniqKey="Yu W" first="Wenbo" last="Yu">Wenbo Yu</name><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name><name sortKey="Zhuang, Ke" sort="Zhuang, Ke" uniqKey="Zhuang K" first="Ke" last="Zhuang">Ke Zhuang</name></noCountry><country name="République populaire de Chine"><region name="Hubei"><name sortKey="Huang, Xiaoxing" sort="Huang, Xiaoxing" uniqKey="Huang X" first="Xiaoxing" last="Huang">Xiaoxing Huang</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001E32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19159014
|texte= A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19159014" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |